Company Overview of MediciNova Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. Its product candidates include MN-166 (ibudilast), an anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis an...
4275 Executive Square
La Jolla, CA 92037
Founded in 2000
Key Executives for MediciNova Inc.
Co-Founder, Chief Executive Officer, President and Executive Director
Total Annual Compensation: $518.9K
Chief Medical Officer
Total Annual Compensation: $344.7K
Head of Japanese Office and Vice President
Total Annual Compensation: $301.8K
Total Annual Compensation: $257.0K
Compensation as of Fiscal Year 2015.
MediciNova Inc. Key Developments
MediciNova Inc. Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis
Jul 25 16
MediciNova Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of fibrosis which includes a broad range of fibrosis /fibrotic disease in different organs due to different causes. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035. The allowed claims cover a method of inhibiting or treating fibrosis using MN-001 or MN-002. MediciNova is currently conducting a Phase 2 clinical trial evaluating MN-001 in idiopathic pulmonary fibrosis (IPF) patients and another Phase 2 clinical trial evaluating MN-001 in nonalcoholic steatohepatitis (NASH).
MediciNova Inc. Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (Ibudilast) in Progressive Ms
Jul 13 16
MediciNova Inc. announced that 50% of patients (127 out of 255 enrolled patients) have completed the 96-week treatment period in the ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS). The trial's external Data Safety Monitoring Board will review the results of an interim efficacy analysis in the fourth quarter of 2016. The purpose of the analysis will be to make recommendations to the National Institute of Neurological Diseases and Stroke (NINDS) regarding the trial.
MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence
Jun 30 16
MediciNova Inc. announced that researchers at the University of California, presented novel findings from further analysis of the completed clinical trial of MN-166 (ibudilast) in alcohol use disorder (AUD) at the 39th Annual Scientific Meeting of the Research Society on Alcoholism on June 27, 2016 at the Hyatt Regency New Orleans in New Orleans, LA. Major highlights from the presentation, “Depressive Symptomatology Moderates the Effects of the Neuroimmune Modulator Ibudilast on Subjective Responses to Alcohol,” include the following: In an intravenous alcohol challenge session in subjects reporting higher levels of depressive symptomatology as measured by the Beck Depressive Inventory (BDI) Scale: ibudilast significantly weakened the alcohol-induced stimulatory effects (p < 0.05), ibudilast significantly decreased alcohol-induced positive mood (p < 0.05), ibudilast significantly decreased ‘wanting’ of alcohol (p < 0.05), and ibudilast showed a trend to decreased ‘liking’ of alcohol (p = 0.061). While ibudilast weakened the alcohol-induced rewarding effects described above during the alcohol challenge, it also enhanced a negative reaction (i.e., feeling of tension/anxiety) (p < 0.05) in subjects reporting higher levels of depressive symptomatology on the BDI.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 1, 2015
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries